Abstract: A sound absorber is configured as a rectangular hexahedral box and forms a porous double-layer Helmholtz resonance sound absorbing structure, at the same time, the sound absorber in the form of a box forms a structural resonance sound absorbing device itself, and the first-order natural mode frequency of the device is identical to that of a wheel air chamber. When the box-type sound absorbing structure is assembled in a wheel, double functions of absorbing acoustic resonance of the wheel air chamber under the organic combination of Helmholtz resonance sound absorption and structural resonance sound absorption can be realized.

Abstract: An automatic lifting display rack includes a display rack body, an elastic device, and a lifting platform. The display rack body has an accommodation space therein. The elastic device is disposed in the accommodation space. The lifting platform is above the elastic device. Corners of the lifting platform are integrally connected with a plurality of first upright posts that are parallel to side walls of the accommodation space. At least one first roller is mounted to each of the first upright posts. The first roller is configured to roll on a corresponding one of the side walls of the accommodation space. The automatic lifting display rack can improve the smoothness and stability of the lifting platform to be moved up and down.

Abstract: The present disclosure discloses a method for synthesizing quinolones intermediates by a continuous flow reaction. Specifically, according to the method, a microchannel reactor is used, which improves the selectivity and conversion rate of the reaction, and the conversion rate of compound ii is increased to more than 95% and the yield is increased to more than 85%; avoids the use of a solvent such as methanol, and methyl tert-butyl ether, etc., in the intermittent reaction process, which simplifies the post-processing method, shortens the overall operation time from about 24 hours to a few minutes, greatly improving the production efficiency, and realizing the continuity and automation of the whole process; and thus makes the product have high purity and high yield, which is suitable for industrial production.

Abstract: A lifting structure of a display rack includes an upright post, a retainer, a lifting support, and a tension spring. The upright post includes a guide rail on an inner corner of the upright post. The retainer is installed on an upper end of the guide rail. The lifting support includes a support portion that is movably fitted in the inner corner of the upright post and a slide portion that is slidably fitted in the guide rail. The support portion is configured to support a bearing plate of the display rack. Upper and lower ends of the tension spring are connected to the retainer and the slide portion, respectively. The lifting structure of the display rack can be lifted and lowered smoothly without shaking.

Abstract: An automatic lifting display rack includes a display rack body, an elastic device, and a lifting platform. The display rack body has an accommodation space therein. The elastic device is disposed in the accommodation space. The lifting platform is above the elastic device. Corners of the lifting platform are integrally connected with a plurality of first upright posts that are parallel to side walls of the accommodation space. At least one first roller is mounted to each of the first upright posts. The first roller is configured to roll on a corresponding one of the side walls of the accommodation space. The automatic lifting display rack can improve the smoothness and stability of the lifting platform to be moved up and down.

Abstract: BTL.010 is a novel human serine proteinase inhibitor of the Kunitz family that exhibits greater potency towards neutral serine proteinases, particularly leukocyte elastase and proteinase 3 than towards trypsin-like proteinases. BTL.010, or variants thereof, may be employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis in which uncontrolled proteolysis due to neutral serine proteinase activity results in tissue damage.

Abstract: The present invention provides methods for modulating angiogenesis by administering anti-angiogenic FGF-19 polypeptides to a subject. Methods of modulating angiogenesis by administering an anti-angiogenic FGF-19 nucleic acid are also provided.

Abstract: BTL.010 is a novel human serine proteinase inhibitor of the Kunitz family that exhibits greater potency towards neutral serine proteinases, particularly leukocyte elastase-, and proteinase 3, than towards trypsin-like proteinases. BTL.010, or variants thereof, may be employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis in which uncontrolled proteolysis due to neutral serine proteinase activity results in tissue damage.